
Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.
Join allergist Dr. Nicole Chase and dermatologist Dr. Jason Hawkes as they dispel common myths in the management of chronic spontaneous urticaria (CSU). They offer practical, empathetic strategies to move beyond unnecessary diagnostics and delays, focusing instead on urgent treatment escalation and effective management to reduce the profound burden of uncontrolled CSU on patients.

Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life

In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses about indirect comparison of biologics for CRSwNP, focusing on clinical outcomes like symptom relief and safety and also highlights dupilumab, omalizumab, and mepolizumab as effective and well-tolerated options.
Join Dr. Miguel Lanz as he explains the clinical utility of FeNO as a biomarker of severe asthma.
Join pediatric respirologist Dr. Sharon Dell and adult respirologist Dr. Simon Couillard as they discuss the prognostic and diagnostic power of asthma biomarkers and their impact on optimizing patient management across all ages.

Drs. Bob Geng and Lawrence Eichenfield highlight a multidisciplinary team approach to patient-centered care in diseases with type 2 inflammation
Join the effort to improve CRSwNP care. World Anosmia Day serves as an opportunity to raise awareness about the loss of the sense of smell. Access some of countless educational resources with ADVENT below.
Professors Bouaziz, Paller, and Irvine discuss the clinical burden of atopic dermatitis, the biomarkers of subclinical control, and evidence of potential disease modification in AD at EADV 2025.

Dr Mario Castro presents the latest clinical data on biologics showcasing their effect on airway remodeling parameters and airway hyperresponsiveness in patients with severe asthma.

Dr. Amy Paller discusses the evolving concepts of early intervention and disease modification in AD and describes potential biomarkers of subclinical control at EADV 2025.

An interactive patient case tool involving a deeper dive into assessing clinical presentation when diagnosing bullous pemphigoid (BP)